The program for the 2018 ICPAD will consist of the following session topics. Please click on preliminary agenda to view the details of the preliminary program and confirmed speakers. The information is subject to change.

Please note that the organizer does not hire any agent or third party to arrange accommodation for delegates.

Abstract presentations

Paper ref #Paper TitleFirst nameLast  nameOrganizationCountry
O1Correlation between nivolumab exposure and treatment outcome in NSCLCSanderBinsErasmus Medical Centre Cancer Institutethe Netherlands
O2A pharmacometric framework for dose individualisation of sunitinib in GISTMaddalenaCentanniUppsala UniversitySweden
O3Therapeutic drug monitoring as a tool to reduce the occurrence of paclitaxel-associated peripheral neuropathy in patients with advanced NSCLCFrancis Ojara WilliamsFreie Universitaet BerlinGermany
O4A Randomized Bayesian Phase 1 Design Combining an MPS-1 Inhibitor with Paclitaxel: a Strategy to Improve Determination of The Incremental Toxicity of a Novel Compound over a Known Backbone TherapyFlorenceAtrafiErasmus University Medical Centrethe Netherlands
O5Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searchesStefanieKrensRadboudumcthe Netherlands
O6Food intervention to make therapy with pazopanib more patient friendly and affordableFloorLubbermanRadboudumcthe Netherlands
O7A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatmentApostolosPapachristosUniversity College London Hospital, Uk And University Of Patras, GreeceUK
O8A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft modelsRhysJonesAstrazenecaUK
O9The Relationship Between Busulphan AUC and the Incidence of Sinusoidal Obstruction Syndrome in Haematopoietic Stem Cell TransplantsParthUpadhyayUniversity of SydneyAustralia
O10Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio RhysJonesAstrazenecaUK
P1Investigation of causes of drug-induced pyrexia in patients with BRAF V600E/K metastatic melanoma treated with dabrafenib and trametinibHannah YejinKimUniversity of SydneyAustralia
P2Effect of patient characteristics on pharmacokinetics of enzalutamide in mCRPC patients GuillemetteBenoistRadboudumcthe Netherlands
P3Analysis of the involvement of cytochrome P450 isoenzymes in the metabolism of antineoplastic medicinesArsenyKirilyukRUP «BELPHARMATSIA»Belarus
P4Influence of the number of tumor size measurements on model-derived tumor size metrics and estimated hazard of deathSreenathM KrishnanUppsala UniversitySweden
P5Mechanistic models of cancer-immune cycle and immunotherapiesVijiChelliahCertara Qsp UKUK
P6PK/PD model for describing the antitumor effect of anti-PD-L1 mAb administered to melanoma bearing mice.Zinnia P.Guillén-ParraUniversity of NavarraSpain
P7Liposome co-encapsulation of doxorubicin and a prodrug of mitomycin-c for pharmacological optimization of combination chemotherapy AlbertoGabizonShaare Zedek MC and Hebrew UniversityIsrael
P8Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. NikkiDe RouwRadboudumcthe Netherlands
P9A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer.  A study of the Southeast Netherlands Breast Cancer Registry.Lotte M.KnapenMaastricht University Medical Centerthe Netherlands
P10Individualized pemetrexed dosing in patients with non-small cell lung cancer or mesothelioma based on renal function to improve treatment response.ReneBoosmanNki-avlthe Netherlands
P11Development and validation of a limited sampling strategy for pemetrexed therapeutic drug monitoring and research purposes.NikkiDe RouwRadboudumcthe Netherlands
P12Novel Niclosamide Stearate Nanoparticles Induce Lysosome Membrane Permeabilization in Triple Negative MDA-MB-231 Breast Cancer CellsPaola MariselNataliniUniversity Of Southern DenmarkDenmark
P13A new method for the determination of total and released docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec®) by LC-MS/MS and its clinical application in plasma and tissues in patients with various tumours CLBraalErasmus Medical Centre Cancer Institutethe Netherlands
P14Polymeric Micelles-based Nanomedicines: Suitable Modulators of Drugs’ Pharmacokinetics and PharmacodynamicsDianaRafaelCibbim-nanomedicine, VhirSpain
P15Targeted Gene Delivery Systems: A Nanomedicine Approach for Breast Cancer Cells Treatment DianaRafaelCibbim-nanomedicine, VhirSpain
P16Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenibFemke M. de ManErasmus Medical Centre Cancer Institutethe Netherlands
P17Impact of curcumin with or without piperine on the pharmacokinetics of tamoxifenKoen G.A.M. HussaartsErasmus Medical Centre Cancer Institutethe Netherlands
P18Effects of Prednisone on Docetaxel Pharmacokinetics in Men with Metastatic Prostate Cancer: A Randomized Drug-drug Interaction StudyBodineBelderbosErasmus Medical Centre Cancer Institutethe Netherlands